June 14-17, 2017
Lugano, Switzerland

14th International Conference on Malignant Lymphoma

14-ICML

POCKET PROGRAM

Printed by courtesy of

Organized in association with:
Foundation for the Research and Cure of Lymphoma in Ticino
and International Extranodal Lymphoma Study Group - IELSG
INDEX

Acknowledgements 3
Onsite Contact Details and Information 4
14-ICML Locations 6
General Information 7
Marquee Parco Ciani 8
Villa Ciani 9
Il Ciani 9
Program at a Glance 10
Scientific Program 15
14-ICML Transport Service 37
14-ICML Contacts 38
ACKNOWLEDGEMENTS

INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML)

PRESIDENT
F. Cavalli, Bellinzona (Switzerland)

CHAIRMAN OF ICML

LOCAL ORGANIZING COMMITTEE
M. Ghielmini, Bellinzona (Switzerland)

ICML LOCAL ORGANIZING COMMITTEE
(based in Bellinzona, Switzerland)
F. Bertoni
A. Moccia
F. Peccatori - European School of Oncology (ESO) representative
D. Rossi
A. Stathis
G. Stüssi
E. Zucca

PRESIDENT OF ICML ADVISORY BOARD
J.O. Armitage, Omaha, NE (USA)

ICML ADVISORY BOARD
E. Campo, Barcelona (Spain)
B.D. Cheson, Washington, D.C. (USA)
N. Chiorazzi, Manhasset, NY (USA)
J.M. Connors, Vancouver, BC (Canada)
R. Dalla-Favera, New York, NY (USA)
S. Dirnhofer, Basel (Switzerland)
M. Dreyling, Munich (Germany)
A. Engert, Cologne (Germany)

The conference organizers wish to thank the following sponsors for their unrestricted financial support:
AbbVie, Inc.
Acerta Pharma
AstraZeneca
Bayer
Bristol-Myers Squibb
Celgene Corporation
Cell Medica
Celltrion Healthcare
Gilead Sciences
Incite Corporation
Inviscribe®
Janssen Pharmaceutical Companies of Johnson & Johnson
Kite Pharma
Med Tech Trading
MorphoSys
MSD
Mundipharma Medical Company
Novartis Pharmaceuticals Corporation
Pfizer Oncology
Roche
Sandoz
Seattle Genetics
Servier Oncology
Takeda Oncology
Teva Oncology
Vifor Pharma

M.F. Fey, Bern (Switzerland)
J.W. Friedberg, Rochester, NY (USA)
G. Gaidano, Novara (Italy)
R.D. Gascoyne, Vancouver, BC (Canada)
P. Gaulard, Créteil (France)
M.K. Gospodarowicz, Toronto, ON (Canada)
E.S. Jaffe, Bethesda, MD (USA)
P.W.M. Johnson, Southampton (UK)
R. Küppers, Essen (Germany)
J.P. Leonard, New York, NY (USA)
T.A. Lister, London (UK)
A.M. Melnick, New York, NY (USA)
K. Ohshima, Kurume (Japan)
A. Pavlovsky, Buenos Aires (Argentina)
M.A. Piris, Madrid (Spain)
S.V. Rajkumar, Rochester, MN (USA)
J.F. Seymour, Melbourne (Australia)
M.A. Shipp, Boston, MA (USA)
L. Specht, Copenhagen (Denmark)
C. Thieblemont, Paris (France)
K. Tobinai, Tokyo (Japan)
U. Vito, Turin (Italy)
A. Younes, New York, NY (USA)
W. Wössmann, Giessen (Germany)

CONFERENCE SECRETARIAT AND LOCAL ORGANIZATION
C. Brentan, O. Lugli, C. Saporiti
Bellinzona (Switzerland)

The conference organizers wish to thank the following contributors for their support:
American Association for Cancer Research – AACR
City of Lugano
Comunità Tariffale Arcobaleno
European Canine Lymphoma Network
European School of Oncology – ESO
European Society for Medical Oncology – ESMO
European Society for Radiotherapy and Oncology – ESTRO
IBSA Foundation for Scientific Research
International Lymphoma Radiation Oncology Group - IROG
Kompetenznetz Maligne Lymphome e.V. (KML)
Leukämiehilfe Rhein-Main g.e.V. - LHRM
Lymphoma Coalition
Schweizerische Patientenorganisation für Lymphombetroffene und Angehörige - ho / noho
Swiss Cancer Research Foundation
Swiss International Air Lines Ltd
Ticino Tourism
Union of Chinese Lymphoma Investigators – UCILI
University of Lugano – USI
(Università della Svizzera Italiana)
14-ICML Registration and Information Desk

Monday, June 12: only by appointments, only for groups
Tuesday, June 13: 08:30 – 19:30
from Wednesday, June 14, to Friday, June 16: 07:30 – 19:00
Saturday, June 17: 07:30 – 12:00

Contacts during the Conference

Cristiana Brentan (scientific program and general information) Tel. +41 76 750 54 65 cristiana.brentan@lymphcon.ch
Orietta Lugli (exhibition, satellite symposia, ancillary meetings) Tel. +41 79 800 24 45 orietta.lugli@lymphcon.ch
Chiara Saporiti (registrations and accounting) Tel. +41 58 866 66 68 registration@lymphcon.ch

Please consider that during the Conference days we will have few chances to check our messages: do not use e-mail for urgencies!

The following services will be available in Palazzo dei Congressi:

– Internet Corner, sponsored by Takeda Oncology
– Speaker Preview Center
– Transport Info Desk, for information on public transports and buses organized by 14-ICML Secretariat
– Currency exchange office (cash only) → the closest automatic cash dispensers / ATM are Cornèr Bank, via Canova 16 and Banca Coop, viale Cattaneo 17A.
– Free refreshment points with water supply, in co-operation with BRITA
– Restrooms:
  Palazzo dei Congressi “Villa Ciani” Il Ciani Building Marquee Parco Ciani Cinema Corso Lugano University
We invite you to attend an AbbVie-sponsored satellite symposium at the 14th International Conference on Malignant Lymphoma (ICML)

NOVEL TREATMENTS IN RELAPSED/REFRACTORY CLL: PRESENT AND FUTURE

Room B, Palazzo dei Congressi, Wednesday, June 14, 2017 19:00–21:00

Chaired by Ulrich Jäger, who will be joined by a renowned international faculty of Davide Rossi, Barbara Eichhorst and Véronique Leblond

This will be an engaging and informative discussion of current and future approaches in the treatment of relapsed/refractory CLL
14-ICML LOCATIONS

---

Palazzo dei Congressi
Piazza Indipendenza 4, 6900 Lugano
Tel. +41 58 866 66 30
Fax: +41 58 866 66 39
E-mail: info@luganoconventions.com

- Main Convention Centre,
  Scientific Sessions

Cinema Corso,
Via G. B. Pioda 4

- Parallel Scientific Sessions,
  Room A overflow area

Lugano University, Via G. Buffi 13
Aula Magna hall

- Parallel Scientific Sessions,
  Room A overflow area

Lugano University, Via G. Buffi 13
Auditorium hall

“Marquee Parco Ciani”
Lugano town park

- Poster Session, Room B overflow area,
  Exhibition Area

Villa Ciani
Lugano town park

- Hospitality Suites and Meeting Rooms,
  Press Room, Sit&Meet Area

Il Ciani Building
Viale C. Cattaneo 5

- Meeting Rooms, Sit&Meet Area

Campo Marzio Parking,
Via Campo Marzio

- 14-ICML transport parking
GENERAL INFORMATION

Certificate of attendance – Evaluation Form

14-ICML program is designated for a maximum of, or up to, 24 European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Certificate of Attendance can be obtained as of FRIDAY, June 16 returning the completed Evaluation Form.

14-ICML is an European Society for Medical Oncology - ESMO supported meeting and is accredited with 25 ESMO-MORA cat. 1 points.

14-ICML is supported by European School of Oncology – ESO.
ICML program is part of the Certificate of Competence in Lymphoma, a 1-year ECTS curriculum of studies academically recognized by Ulm University. For further information, please visit www.eso.net.

14-ICML Educational Book

Articles of the Educational Symposia and Meet the Professor sessions are included in the 14-ICML Educational Book, supplement to "Hematological Oncology" and published by Wiley. The supplement is distributed to attendees on site and also available online at the ICML official website (www.lymphcon.ch) and at the Wiley Online Library website (http://onlinelibrary.wiley.com).

14-ICML Abstract Book

All selected abstracts are included in the 14-ICML Abstract Book, published by Wiley and available online at the ICML official website (www.lymphcon.ch) and at the Wiley Online Library website (http://onlinelibrary.wiley.com).

Best Abstract Merit Award and Travel Grants

The Best Abstract Merit Award and three Travel Grants, sponsored by the Swiss Cancer Research Foundation, have been assigned to the following young investigators (less than 35 years), on the basis of the evaluation results:

– Paula Cramer, Cologne (Germany)  – Angelo Fama, Rochester, MN (USA)
– Sarah Huet, Pierre Bénite (France)  – Luca Frigeni, Pavia (Italy)

Insurance

The 14-ICML Organizers bear no responsibility for untoward events in connection with, before, during and after the congress. Participants are strongly advised to take out their own personal and travel insurance coverage.

NB: charge of replacement of lost badge: CHF 100.
MARQUEE PARCO CIANI

Poster Session
Room B Overflow Area
Exhibition Area
Coffee and Lunch Area

Opening hours:
Wednesday June 14 08:30 – 18:30
Thursday June 15 08:30 – 18:30
Friday June 16 08:30 – 18:30
VILLA CIANI

Meeting Rooms
Press Room
Sit&Meet Area

Opening hours:
from Tuesday, June 13 to Friday, June 16 from 08:00 to 20:00

Ground Floor
Hospitality Suite nr 1 MUNDIPHARMA MEDICAL COMPANY
Business Centre nr 2 & 3 TAKEDA ONCOLOGY
Hospitality Suite nr 4 & 5 GILEAD SCIENCES
Meeting Room nr 6 BAYER

First Floor
Business Centre nr 7 & 8 CELGENE CORPORATION

Second Floor
Meeting Room nr 9 KOMPETENZNETZ MALIGNE LYMPHOMES E.V. (KML)
Meeting Room nr 10 ROCHE
ICML Press Room
Sit&Meet Area

IL CIANI BUILDING

Meeting Rooms
Sit&Meet Area

Opening hours:
from Tuesday, June 13 to Friday, June 16 from 07:00 to 21:00
Saturday, June 17 from 07:00 to 18:00

Meeting Room nr 1 GILEAD SCIENCES
Meeting Room nr 2 & 3 CELGENE CORPORATION
Meeting Room nr 4 MSD
Meeting Room nr 5 ACERTA PHARMA – ASTRA ZENECA
Meeting Room nr 6 INCYTE CORPORATION
Meeting Room nr 7 ABBVIE, INC.

Complimentary internet wi-fi access is available for conference delegates throughout the venue. To access wi-fi, please use the following information:
network name (SSID): 14-ICML
password (PSK): Lugano2017
Please note that wi-fi connection speed and performance depend on number of simultaneous accesses.

The 14-ICML Application is available thanks to
It can be downloaded from the Apple App Store or Google Play.
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15</td>
<td>PCL</td>
<td>CLOSED WORKSHOP Design of clinical trials: Biological and clinical</td>
</tr>
<tr>
<td></td>
<td>ground floor</td>
<td>endpoints in the design of future clinical trials (by invitation only)</td>
</tr>
<tr>
<td></td>
<td>Room A</td>
<td>08:00-17:30 Organized in co-operation with American Association for</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer Research - AACR and European School of Oncology - ESO</td>
</tr>
<tr>
<td>7:30</td>
<td>PCL</td>
<td>CELLTRION HEALTHCARE symposium room BI (12:00-14:00)</td>
</tr>
<tr>
<td></td>
<td>first floor</td>
<td>NOVARTIS PHARMACEUTICALS COMPANY symposium room BI (12:00-14:00)</td>
</tr>
<tr>
<td>7:45</td>
<td>PCL</td>
<td>GILEAD SCIENCES symposium room A (15:30-17:30)</td>
</tr>
<tr>
<td></td>
<td>first floor</td>
<td>BRISTOL-MYERS SQUIBB symposium room BI (15:30-17:30)</td>
</tr>
<tr>
<td>8:00</td>
<td>PCL</td>
<td>SERVIER ONCOLOGY symposium room BI (15:30-17:30)</td>
</tr>
<tr>
<td></td>
<td>first floor</td>
<td>WORKSHOP - Novel issues in the combined modality treatment of</td>
</tr>
<tr>
<td></td>
<td>Room B I</td>
<td>lymphomas (open to all 14-ICML participants)</td>
</tr>
<tr>
<td></td>
<td>Room B II</td>
<td>15:00-17:30 Organized by International Lymphoma Radiation Oncology</td>
</tr>
<tr>
<td></td>
<td>Auditorium</td>
<td>Group - ILROG</td>
</tr>
<tr>
<td>8:15</td>
<td>PCL</td>
<td>WORKSHOP - Novel issues in the combined modality treatment of</td>
</tr>
<tr>
<td></td>
<td>first floor</td>
<td>lymphomas (open to all 14-ICML participants)</td>
</tr>
<tr>
<td>8:30</td>
<td>PCL</td>
<td>GILEAD SCIENCES symposium room A (19:00-21:00)</td>
</tr>
<tr>
<td></td>
<td>first floor</td>
<td>BAYER symposium room BI (19:00-21:00)</td>
</tr>
<tr>
<td>8:45</td>
<td>PCL</td>
<td>TAKEDA ONCOLOGY symposium room BI (19:00-21:00)</td>
</tr>
<tr>
<td></td>
<td>Auditorium</td>
<td>WORKSHOP - Novel issues in the combined modality treatment of</td>
</tr>
<tr>
<td></td>
<td>Aula Magna</td>
<td>lymphomas (open to all 14-ICML participants)</td>
</tr>
<tr>
<td>9:00</td>
<td>PCL</td>
<td>Room A (19:00-21:00)</td>
</tr>
<tr>
<td></td>
<td>Auditorium</td>
<td>BAYER symposium room BI (19:00-21:00)</td>
</tr>
<tr>
<td>9:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>9:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>9:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>10:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>10:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>10:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>10:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>11:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>11:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>11:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>11:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>12:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>12:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>12:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>12:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>13:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>13:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>13:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>13:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>14:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>14:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>14:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>14:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>15:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>15:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>15:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>15:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>16:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>16:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>16:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>16:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>17:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>17:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>17:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>17:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>18:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>18:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>18:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>18:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>19:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>19:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>19:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>19:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>20:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>20:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>20:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>20:45</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>21:00</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>21:15</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
<tr>
<td>21:30</td>
<td>PCL</td>
<td>Room B II (19:00-21:00)</td>
</tr>
</tbody>
</table>
WEDNESDAY, JUNE 14

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15</td>
<td>POSTER SESSION SET UP (8:30-12:00)</td>
</tr>
<tr>
<td>7:30</td>
<td>Meet the Professor: J.W. FRIEDBERG Chemotherapy-free treatment of indolent lymphomas (8:30-9:15)</td>
</tr>
<tr>
<td>7:45</td>
<td>Meet the Professor: L. QUINTANILLA-M. The 2016 updated WHO classification (8:30-9:15)</td>
</tr>
<tr>
<td>8:00</td>
<td>Meet the Professor: M. HALEX Role and timing of new drugs in CLL (8:30-9:15)</td>
</tr>
<tr>
<td>8:15</td>
<td>Meet the Professor: J.G. GRIBBEN The role of stem cell transplant for lymphoma in 2017 (8:30-9:15)</td>
</tr>
<tr>
<td>8:30</td>
<td>Meet the Professor: L. QUINTANILLA-M. The 2016 updated WHO classification (8:30-9:15)</td>
</tr>
<tr>
<td>8:45</td>
<td>Meet the Professor: M. HALLEK Role and timing of new drugs in CLL (8:30-9:15)</td>
</tr>
<tr>
<td>9:00</td>
<td>Meet the Professor: J.G. GRIBBEN The role of stem cell transplant for lymphoma in 2017 (8:30-9:15)</td>
</tr>
<tr>
<td>9:15</td>
<td>Meet the Professor: M. RADERER The multiple facets of marginal zone lymphomas (9:30-10:15)</td>
</tr>
<tr>
<td>9:30</td>
<td>Meet the Professor: M. HALLEK Role and timing of new drugs in CLL (8:30-9:15)</td>
</tr>
<tr>
<td>9:45</td>
<td>Meet the Professor: J.G. GRIBBEN The role of stem cell transplant for lymphoma in 2017 (8:30-9:15)</td>
</tr>
<tr>
<td>10:00</td>
<td>Meet the Professor: M. RADERER The multiple facets of marginal zone lymphomas (9:30-10:15)</td>
</tr>
<tr>
<td>10:15</td>
<td>COFFEE (10:15-10:35)</td>
</tr>
<tr>
<td>10:30</td>
<td>Educational Symposium AGGRESSIVE LYMPHOMAS (10:35-12:00)</td>
</tr>
<tr>
<td>10:45</td>
<td>Educational Symposium IMMUNOTHERAPY IN LYMPHOMAS (10:35-12:00)</td>
</tr>
<tr>
<td>11:00</td>
<td>Educational Symposium IMMUNOTHERAPY IN LYMPHOMAS (10:35-12:00)</td>
</tr>
<tr>
<td>11:15</td>
<td>Meet the Professor: K. TOBINAI Disease-oriented treatment of T-cell lymphomas (9:30-10:15)</td>
</tr>
<tr>
<td>11:30</td>
<td>Meet the Professor: L. QUINTANILLA-M. The 2016 updated WHO classification (8:30-9:15)</td>
</tr>
<tr>
<td>11:45</td>
<td>Meet the Professor: M. HALLEK Role and timing of new drugs in CLL (8:30-9:15)</td>
</tr>
<tr>
<td>12:00</td>
<td>LUNCH TIME and POSTER VIEWING (13:00-14:00)</td>
</tr>
<tr>
<td>12:15</td>
<td>OPENING OF THE CONFERENCE HENRY KAPLAN MEMORIAL LECTURE (13:00-14:00)</td>
</tr>
<tr>
<td>12:30</td>
<td>PLENARY SESSION (14:00-15:15)</td>
</tr>
<tr>
<td>12:45</td>
<td>AACR-ICML JOINT SESSION - CANCER IMMUNOTHERAPY (15:40-16:40)</td>
</tr>
<tr>
<td>13:00</td>
<td>AULA MAGNA</td>
</tr>
<tr>
<td>13:15</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>13:30</td>
<td>“Focus on...” session PET/CT VISUAL ASSESSMENT AND BEYOND (17:00-18:00)</td>
</tr>
<tr>
<td>13:45</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>14:00</td>
<td>“Focus on...” session PET/CT VISUAL ASSESSMENT AND BEYOND (17:00-18:00)</td>
</tr>
<tr>
<td>14:15</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>14:30</td>
<td>“Focus on...” session PET/CT VISUAL ASSESSMENT AND BEYOND (17:00-18:00)</td>
</tr>
<tr>
<td>14:45</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>15:00</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>15:15</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>15:30</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>15:45</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>16:00</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>16:15</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>16:30</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>16:45</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>17:00</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>17:15</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>17:30</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>17:45</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>18:00</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>18:15</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>18:30</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>18:45</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>19:00</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>19:15</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>19:30</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>19:45</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>20:00</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>20:15</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>20:30</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>20:45</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>21:00</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>21:15</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>21:30</td>
<td>“Focus on...” session CLASSICAL THERAPIES FOR FL (17:00-18:00)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7:15</td>
<td><strong>POSTER SESSION</strong> (from 8:30 to 18:30)</td>
</tr>
<tr>
<td>7:30</td>
<td><strong>POSTER SESSION</strong></td>
</tr>
<tr>
<td>7:45</td>
<td><strong>POSTER SESSION</strong></td>
</tr>
<tr>
<td>8:00</td>
<td>Meet the Professor: C. THEBLEMENT Management of aggressive lymphomas in the very elderly patients (8:00-8:45)</td>
</tr>
<tr>
<td>8:15</td>
<td>Meet the Professor: A. YOUNES Clinical applications of genome studies (8:00-8:45)</td>
</tr>
<tr>
<td>8:30</td>
<td>Meet the Professor: P.W.M. JOHNSON Response-adapted therapy in HL (8:00-8:45)</td>
</tr>
<tr>
<td>8:45</td>
<td>Meet the Professor: J.W. FRIEDBERG Chemotherapy-free treatment of follicular lymphomas (8:00-8:45)</td>
</tr>
<tr>
<td>9:00</td>
<td>Clinical case discussion: HODGKIN LYMPHOMA (09:00-10:30)</td>
</tr>
<tr>
<td>9:15</td>
<td>SESSION 1 LYMPHOMA BIOLOGY (9:00-10:30)</td>
</tr>
<tr>
<td>9:45</td>
<td>SESSION 2 - PRIMARY MEDIASTINAL B-CELL LYMPHOMA (11:00-12:00)</td>
</tr>
<tr>
<td>10:00</td>
<td>Clinical case discussion: T-CELL LYMPHOMAS (09:00-10:30)</td>
</tr>
<tr>
<td>10:15</td>
<td>COFFEE (10:30-11:00)</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>SESSION 3 - HODGKIN LYMPHOMA</strong> (13:45-15:15)</td>
</tr>
<tr>
<td>11:15</td>
<td>SESSION 3 - HODGKIN LYMPHOMA</td>
</tr>
<tr>
<td>11:30</td>
<td>SESSION 3 - HODGKIN LYMPHOMA</td>
</tr>
<tr>
<td>11:45</td>
<td><strong>SESSION 4 - TARGETING THE BCR PATHWAYS</strong></td>
</tr>
<tr>
<td>12:00</td>
<td><strong>LUNCH TIME AND POSTER VIEWING</strong></td>
</tr>
<tr>
<td>12:15</td>
<td><strong>GIANNI BONADONNA MEMORIAL LECTURE</strong> (13:00-13:45)</td>
</tr>
<tr>
<td>12:30</td>
<td><strong>GIANNI BONADONNA MEMORIAL LECTURE</strong> (13:00-13:45)</td>
</tr>
<tr>
<td>12:45</td>
<td><strong>GIANNI BONADONNA MEMORIAL LECTURE</strong> (13:00-13:45)</td>
</tr>
<tr>
<td>14:00</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>14:15</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>14:30</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>14:45</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>15:00</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>15:15</td>
<td>COFFEE (15:15-15:30)</td>
</tr>
<tr>
<td>15:30</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>15:45</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>16:00</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>16:15</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>16:30</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>16:45</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>17:00</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>17:15</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>17:30</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>17:45</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>18:00</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>18:15</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>18:30</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>18:45</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>19:00</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>19:15</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>19:30</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>19:45</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>20:00</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>20:15</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>20:30</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>20:45</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>21:00</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>21:15</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>21:30</td>
<td><strong>SESSION 5 - T-CELL LYMPHOMAS</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7:15</td>
<td>Meet the Professor: M. HALLEK Role and Timing of new drugs in CLL (08:30-08:45)</td>
</tr>
<tr>
<td>7:45</td>
<td>Meet the Professor: M. RADERER The multiple facets of marginal zone lymphomas (08:30-08:45)</td>
</tr>
<tr>
<td>8:00</td>
<td>Meet the Professor: M. RADERER The 2016 updated WHO classification (08:30-08:45)</td>
</tr>
<tr>
<td>8:45</td>
<td>Meet the Professor: F.E. VAN LEEUWEN Late sequelae in Hodgkin lymphoma survivors (08:30-08:45)</td>
</tr>
<tr>
<td>9:00</td>
<td>Meet the Professor: C. THIEBLEMONT Management of aggressive lymphomas in the very elderly patients (08:30-08:45)</td>
</tr>
<tr>
<td>9:15</td>
<td>Clinical case discussion: AGGRESSIVE LYMPHOMAS (09:00-10:30) Room B Markree</td>
</tr>
<tr>
<td>9:45</td>
<td>Clinical case discussion: INDOLENT LYMPHOMAS (09:00-10:30) Marquee</td>
</tr>
<tr>
<td>10:00</td>
<td>Clinical case discussion: DIFFICULT PATHOLOGICAL CASES (09:00-10:30)</td>
</tr>
<tr>
<td>10:45</td>
<td>COFFEE (10:30-10:50)</td>
</tr>
<tr>
<td>11:00</td>
<td>SESSION 7 ADVANCES IN CLL Room A - B - Marquee Cinema Corso - Aula Magna (10:50-12:05)</td>
</tr>
<tr>
<td>11:30</td>
<td>LUNCH TIME AND POSTER VIEWING Postersession: 8:30-16:30</td>
</tr>
<tr>
<td>12:00</td>
<td>JOHN ULTMANN MEMORIAL LECTURE Room A - B - Marquee Cinema Corso - Aula Magna (13:00-13:45)</td>
</tr>
<tr>
<td>12:30</td>
<td>IBSA FOUNDATION SPECIAL FORUM BASIC MECHANISMS OF CANCER IMMUNOTHERAPY (open to all 14-ICML participants) 14:15-17:15 Organized by IBSA Foundation for Scientific Research pre-registration is appreciated at <a href="http://www.ibsafoundation.org">www.ibsafoundation.org</a> (free session)</td>
</tr>
<tr>
<td>12:45</td>
<td>JOINT ICML SESSION - NK/T-cell lymphoma (open to all 14-ICML attendees) 14:15-17:05 Organized in co-operation with Union of Chinese Lymphoma Investigators - UCL</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Workshop</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7:15</td>
<td>SPECIAL SESSION CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING (08:00-10:30)</td>
</tr>
<tr>
<td></td>
<td>compulsory pre-registration up to 30 attendees at <a href="mailto:registration@lymphcon.ch">registration@lymphcon.ch</a></td>
</tr>
<tr>
<td></td>
<td>(fee CHF 50.-)</td>
</tr>
<tr>
<td>7:30</td>
<td></td>
</tr>
<tr>
<td>7:45</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td></td>
</tr>
<tr>
<td>8:15</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
</tr>
<tr>
<td>8:45</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>CLOSURE AND FAREWELL (11:40-11:50)</td>
</tr>
<tr>
<td>12:15</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
</tr>
<tr>
<td>19:15</td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
</tr>
<tr>
<td>20:15</td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
</tr>
<tr>
<td>20:45</td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
</tr>
<tr>
<td>21:15</td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
</tr>
</tbody>
</table>
CONFERENCE SCHEDULE

ESO 2017 FULL IMMERSION COURSE ON LEUKAEMIA AND LYMPHOMA
Chairmen: J.O. Armitage (USA), M.F. Fey (Switzerland) and E. Zucca (Switzerland)
Hosting Chair: F. Cavalli (Switzerland)
Held in co-operation with the European School of Oncology - ESO
Date: June 10 – 13, 2017
Location: Monte Verità, Ascona

Monday, June 12, 2017
09:00 – 17:45
Room E
ESMIT/ESO CASE-BASED LEARNING COURSE ON [18F]FDG PET/CT IN THE MANAGEMENT OF LYMPHOMA
Compulsory pre-registration. Registration form can be downloaded at www.eanm.org and sent to esmit@eanm.org

Tuesday, June 13, 2017
08:00 – 17:30
Auditorium (Lugano University)
CLOSED WORKSHOP - DESIGN OF CLINICAL TRIALS: BIOLOGICAL AND CLINICAL ENDPOINTS IN THE DESIGN OF FUTURE CLINICAL TRIALS
Co-chairs: A. Younes, New York, NY (USA) and E. Zucca, Bellinzona (Switzerland)
Organized in co-operation with American Association for Cancer Research – AACR and European School of Oncology – ESO
by invitation only
12:00 – 14:00  2 parallel symposia
Room B1
CELLTRION HEALTHCARE
THE 1ST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
Chair: C. Buske, Ulm (Germany)
Room BII
NOVARTIS PHARMACEUTICALS CORPORATION
CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF AGGRESSIVE B CELL LYMPHOMAS
Chair: S.J. Schuster, Philadelphia, PA (USA)
15:00 – 17:30
Aula Magna (Lugano University)
WORKSHOP - NOVEL ISSUES IN THE COMBINED MODALITY TREATMENT OF LYMPHOMAS
Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark) Organized by International Lymphoma Radiation Oncology Group - ILROG
open to all 14-ICML attendees
PART 1: IMMUNOMODULATORY TREATMENT IN THE COMBINED MODALITY SETTING
15:00
IMMUNOMODULATORY TREATMENT AND RADIATION THERAPY IN LYMPHOMAS
T.M. Illidge, Manchester (UK)
15:15
IMMUNOMODULATORY TREATMENT, ALONE OR IN COMBINATION WITH OTHER TREATMENT MODALITIES IN THE TREATMENT OF LYMPHOMAS
C. Moskowitz, New York, NY (USA)
15:30  GENERATING AN ABSCOPAL EFFECT BY RADIOTHERAPY FOLLOWED BY CHECKPOINT INHIBITORS IN INDOLENT LYMPHOMAS
M.L. Palomba, New York, NY (USA)

15:45  PANEL DISCUSSION
T.M. Illidge, Manchester (UK), C. Moskowitz, New York, NY (USA), M.L. Palomba, New York, NY (USA), M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark)

16:00 - 16:30  COFFEE BREAK - inside Aula Magna (Lugano University) for workshop attendees

PART 2: NK/T-CELL LYMPHOMAS, AN EMERGING LYMPHOMA TYPE WITH SPECIAL ISSUES

16:30  NK/T-CELL LYMPHOMAS IN ASIA. TREATMENT PRINCIPLES. WHAT RADIATION THERAPY? WHAT CHEMOTHERAPY REGIMEN? WHEN TO COMBINE AND WHEN TO USE SINGLE MODALITY?
M. Oguchi, Tokyo (Japan)

16:45  NK/T-CELL LYMPHOMAS IN THE WESTERN WORLD. EXPERIENCE WITH COMBINED MODALITY TREATMENT AT MSKCC
S.M. Horwitz, New York, NY (USA)

17:00  THE BEIJING EXPERIENCE WITH RADIATION ALONE
Y.-X. Li, Beijing (China)

17:15  PANEL DISCUSSION
M. Oguchi, Tokyo (Japan), S.M. Horwitz, New York, NY (USA), Y.-X. Li, Beijing (China), L. Specht, Copenhagen (Denmark) and M.K. Gospodarowicz, Toronto (Canada)

15:30 – 17:30  3 parallel symposia
Room A  GILEAD SCIENCES
ADVANCING PROGNOSTICATION AND TARGETED STRATEGIES IN CLL AND FL
Co-chairs: M. Ghielmini, Bellinzona (Switzerland) and M. Hallek, Cologne (Germany)

Room B I  BRISTOL-MYERS SQUIBB
IMMUNO-ONCOLOGY RESEARCH IN LYMPHOMA: PRESENT AND FUTURE
Chair: G. Collins, Oxford (UK)

Room B II  SERVIER ONCOLOGY
MANAGEMENT OF MULTIPLY RELAPSED AGGRESSIVE NHL: NEW PERSPECTIVES
Co-chairs: R. Pettengell, London (UK) and E. Van Den Neste, Brussels (Belgium)

19:00 – 21:00  3 parallel symposia
Room A  ROCHE
IMPROVING TREATMENT STRATEGIES FOR PATIENTS WITH FOLLICULAR LYMPHOMA: HOW TO TRANSLATE NOVEL STUDY DATA INTO CLINICAL PRACTICE
Chair: B.D. Cheson, Washington D.C. (USA)

Room B I  BAYER
SHIFTING PARADIGMS IN THE MANAGEMENT AND TREATMENT OF INDOLENT NHL
Co-chairs: M. Ghielmini, Bellinzona (Switzerland) and M. Dreyling, Munich (Germany)

Room B II  TAKEDA ONCOLOGY
TARGETING CD30 IN LYMPHOMA: A MARKER FOR CHANGE?
Co-chairs: A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 12:00</td>
<td>POSTER SESSION SET UP</td>
<td>Marquee</td>
<td></td>
</tr>
<tr>
<td>08:30 – 09:15</td>
<td>Article &quot;MEET THE PROFESSOR&quot; SESSIONS</td>
<td>Room A</td>
<td>CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPHOMAS</td>
</tr>
<tr>
<td></td>
<td>number II</td>
<td></td>
<td>J.W. Friedberg, Rochester, NY (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>repeated on Thursday, June 15, in Aula Magna (Lugano University)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room B and Marquee</td>
<td>THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS</td>
</tr>
<tr>
<td></td>
<td>VI</td>
<td></td>
<td>L. Quintanilla-Martinez, Tuebingen (Germany)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>repeated on Friday, June 16 in Cinema Corso</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cinema Corso IV</td>
<td>ROLE AND TIMING OF NEW DRUGS IN CLL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M. Hallek, Cologne (Germany)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>repeated on Friday, June 16, in Room A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Auditorium III</td>
<td>THE ROLE OF STEM CELL TRANSPLANT FOR LYMPOMA IN 2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J.G. Gribben, London (UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>repeated today at 09:30 in Auditorium (Lugano University)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aula Magna I</td>
<td>THE COSTS OF CARE IN HAEMATOLOGICAL CANCERS: HEALTH ECONOMIC ISSUES</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M.F. Fey, Bern (Switzerland)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>offered only once</td>
</tr>
<tr>
<td>09:30 – 10:15</td>
<td>5 parallel sessions</td>
<td>Room A V</td>
<td>RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPOMA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>P.W.M. Johnson, Southampton (UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>repeated on Thursday, June 15, in Cinema Corso</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room B and Marquee</td>
<td>DISEASE-ORIENTED TREATMENT OF T-CELL LYMPOMAS</td>
</tr>
<tr>
<td></td>
<td>IX</td>
<td></td>
<td>K. Tobinai, Tokyo (Japan)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cinema Corso XI</td>
<td>CLINICAL APPLICATIONS OF GENOME STUDIES</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A. Younes, New York, NY (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>repeated only once</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Auditorium III</td>
<td>THE ROLE OF STEM CELL TRANSPLANT FOR LYMPOMA IN 2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J.G. Gribben, London (UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aula Magna VII</td>
<td>THE MULTIPLE FACETS OF MARGINAL ZONE LYMPOMAS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M. Raderer, Vienna (Austria)</td>
</tr>
<tr>
<td>10:15 – 10:35</td>
<td>COFFEE BREAK</td>
<td>Marquee</td>
<td></td>
</tr>
<tr>
<td>10:35 – 12:00</td>
<td>EDUCATIONAL SYMPOSIA</td>
<td>Room A, Cinema Corso and Aula Magna</td>
<td>AGGRESSIVE LYMPHOMAS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chair: E. Campo, Barcelona (Spain)</td>
</tr>
<tr>
<td></td>
<td>XIII</td>
<td></td>
<td>MOLECULAR GENETICS OF AGGRESSIVE B CELL LYMPHOMAS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>R. Dalla-Favera, New York, NY (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>XIV PATHOLOGY AND CLASSIFICATION OF AGGRESSIVE MATURE B-CELL LYMPHOMAS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E. Campo, Barcelona (Spain)</td>
</tr>
</tbody>
</table>
XV TREATMENT OF AGGRESSIVE B-CELL LYMPHOMAS
S.M. Smith, Chicago, IL (USA)

IMMUNOTHERAPY IN LYMPHOMAS
Chair: S.M. Ansell, Rochester, MN (USA)

XVI IMMUNOLOGY
F. Caligaris-Cappio, Milan (Italy)
CAR T-CELLS
D.G. Maloney, Seattle, WA (USA)
CHECKPOINT INHIBITORS
S.M. Ansell, Rochester, MN (USA)

12:00 – 18:30 Abstract POSTER SESSION
(number (printing and delivery of the posters sponsored by Takeda Oncology)

140-163 PATHOLOGY AND BIOLOGY
164-177 HODGKIN LYMPHOMA
178-204 AGGRESSIVE LYMPHOMAS
205-214 MANTLE CELL LYMPHOMA
215-234 INDOLENT LYMPHOMAS
235-241 CLL
242-257 NK and T-CELL LYMPHOMAS
258-289 NEW DRUG DEVELOPMENT

LUNCH TIME AND POSTER VIEWING

13:00 – 14:00
OPENING OF THE CONFERENCE
WELCOME AND INTRODUCTORY REMARKS
F. Cavalli, Bellinzona (Switzerland)

HENRY KAPLAN MEMORIAL LECTURE AND ICML PRIZE
Laudatio: A. Lanzavecchia, Bellinzona (Switzerland)

001 IMMUNOTHERAPY COMES OF AGE TO TREAT LYMPHOMAS
R. Levy, Stanford, CA (USA)

PLENARY SESSION
Co-chairs: J.M. Vose, Omaha, NE (USA) and J.W. Friedberg, Rochester, NY (USA)

14:00 004 INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY
OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS
WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN
LYMPHOMAS
F. Morschhauser, Lille (France)

Discussant: T.E. Witzig, Rochester, MN (USA)

14:25 005 CRISPR-Cas9 GENETIC SCREENS UNCOVER A B CELL
RECEPTOR-MYD88 SUPERPATHWAY IN DIFFUSE LARGE B CELL
LYMPHOMA
R.M. Young, Bethesda, MD (USA)

Discussant: R. Dalla-Favera, New York, NY (USA)
BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)

P. Cramer, Cologne (Germany)

Best Abstract Merit Award, sponsored by Swiss Cancer League Foundation

Discussant: D. Rossi, Bellinzona (Switzerland)

COFFEE BREAK

GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS

S.J. Schuster, Philadelphia, PA (USA)

AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1

S.S. Neelapu, Houston, TX (USA)

WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM MALIGNANT MELANOMA?

A.M.M. Eggermont, Villejuif (France)

WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER?

R. Stahel, Zurich (Switzerland)

BREAK

“FOCUS ON…” SESSIONS

5 parallel sessions

OUTCOME OF CURATIVE RADIOThERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF 18F-FDG PET-CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG

J.L. Brady, London (UK)

CVP OR R-CVP GIVEN AFTER INVOLVED-FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I-II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL

M.P. MacManus, Melbourne (Australia)

RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO

E. Hoster, Munich (Germany)
DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL
R. Pettengell, London (UK)

LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY
S. Luminari, Reggio Emilia (Italy)

CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS
C. Sarkozy, Pierre Bénite (France)

PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) FOR PATIENTS WITH EARLY STAGE HODGKIN LYMPHOMA ENROLLED IN THE STANDARD ARM OF THE H10 (EORTC/LYSA/FIL) TRIAL
A. Cottereau, Paris (France)

BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET-ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE
A.J. Moskowitz, New York, NY (USA)

CAN BASELINE PET-CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033)
L.C. Pike, London (UK)

CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL)
L. Rigacci, Florence (Italy)

PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY
J. Trotman, Sydney (Australia)

FDG-PET AS A BIOMARKER OF RESPONSE IN DLBCL: THE HOVON 84 STUDY EXPERIENCE
C.N. Burggraaff, Amsterdam (The Netherlands)

NON-MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND CLINICAL SERIES OF 17 CASES FROM THE LYSA
C. Sarkozy, Pierre Bénite (France)

FOXP1 EXPRESSION IS INVERSELY CORRELATED WITH EZH2 MUTATION STATUS AND PREDICTS POOR FAILURE-FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY
A. Mottok, Vancouver (Canada)
17:20 025  ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R-CHOP
C. Keane, Woolloongabba (Australia)

17:30 026  CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY
M. Klanova, Prague (Czech Republic)

17:40 027  NKPA46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY
M. Cheminant, Paris (France)

17:50 028  ADULT PATIENTS WITH CAEBV-LIKE FEATURES: A DISTINCT SUBTYPE OF EPSTEIN-BARR VIRUS POSITIVE T/NK-CELL LYMPHOPROLIFERATIVE DISORDER
K. Kawamoto, Kurume (Japan)

Auditorium  NOVEL ANTI-LYMPHOMA DRUGS
(Lugano   Chair: T.E. Witzig, Rochester, MN (USA)

17:00 029  PHARMACOLOGICAL ACTIVITY OF CB-103 IN HAEMATOLOGICAL MALIGNANCIES – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION
D. Weber, Basel (Switzerland)

17:10 030  ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B-CELL NON-HODGKIN LYMPHOMA
P. Pérez-Galán, Barcelona (Spain)

17:20 031  A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY
S. Le Gouill, Nantes (France)

17:30 032  PHASE I STUDY OF IPH4102, ANTI-KIR3DL2 MAB, IN RELAPSED/REFRACTORY CUTANEOUS T-CELL LYMPHOMAS (CTCL): DOSE-ESCALATION SAFETY, BIOMARKER AND CLINICAL ACTIVITY RESULTS
M. Bagot, Paris (France)

17:40 033  A PHASE 1 STUDY OF THE ANTI-CD37 ANTIBODY-DRUG CONJUGATE AGS67E IN ADVANCED LYMPHOID MALIGNANCIES. INTERIM RESULTS
A. Sawas, New York, NY (USA)

17:50 034  FIRST CLINICAL RESULTS OF ADCT-402, A NOVEL PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B-CELL LINEAGE NHL
B.S. Kahl, St. Louis, MO (USA)

Aula Magna  CHEMOTHERAPY-FREE COMBINATIONS
(Lugano   Chair: S.M. Smith, Chicago, IL (USA)

17:00 035  FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
P. Martin, New York, NY (USA)
<table>
<thead>
<tr>
<th>Time</th>
<th>Article number</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:10</td>
<td>036</td>
<td>L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) – A SINGLE-ARM PHASE II STUDY</td>
<td>Lyon (France)</td>
</tr>
<tr>
<td>17:20</td>
<td>037</td>
<td>A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA</td>
<td>Lille (France)</td>
</tr>
<tr>
<td>17:30</td>
<td>038</td>
<td>PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPOMAS (NHL)</td>
<td>Villejuif (France)</td>
</tr>
<tr>
<td>17:40</td>
<td>039</td>
<td>PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPOMA, MANTLE CELL LYMPOMA, AND FOLLICULAR LYMPOMA</td>
<td>New York, NY (USA)</td>
</tr>
<tr>
<td>17:50</td>
<td>040</td>
<td>UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR-1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL</td>
<td>Boston, MA (USA)</td>
</tr>
</tbody>
</table>

- **Thursday, June 15, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Article number</th>
<th>Presentation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 08:45</td>
<td></td>
<td><strong>MEET THE PROFESSOR SESSIONS</strong> 5 parallel sessions</td>
<td></td>
</tr>
<tr>
<td>Room A</td>
<td>VIII</td>
<td>MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS</td>
<td>Paris (France)</td>
</tr>
<tr>
<td>Room B</td>
<td>XI</td>
<td>CLINICAL APPLICATIONS OF GENOME STUDIES</td>
<td>New York, NY (USA)</td>
</tr>
<tr>
<td>Cinema Corso</td>
<td>V</td>
<td>RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPOMA</td>
<td>Southampton (UK)</td>
</tr>
<tr>
<td>Auditorium</td>
<td>XII</td>
<td>ALCL AND PTCL: WHAT CAN PEDIATRIC AND ADULT ONCOLOGISTS LEARN FROM EACH OTHER?</td>
<td>Aarhus (Denmark)</td>
</tr>
<tr>
<td>Aula Magna</td>
<td>II</td>
<td>CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPOMAS</td>
<td>Rochester, NY (USA)</td>
</tr>
</tbody>
</table>

- **Posters Session**: Wednesday, June 14, 2017 (continued)
“CASE DISCUSSION” SESSIONS
California vs Germany
4 parallel sessions

Room A
HODGKIN LYMPHOMA
Chair: C. Moskowitz, New York, NY (USA)
Discussants: R.H. Advani, Stanford vs P. Borchmann, Cologne

Cinema Corso
T-CELL LYMPHOMAS
Chair: J.M. Vose, Omaha, NE (USA)
Discussants: L.C. Pinter-Brown, Orange vs G. Wulf, Goettingen

Auditorium (Lugano University)
PEDIATRIC AND ADOLESCENT LYMPHOMAS
Chair: W. Wössmann, Giessen (Germany)
Discussants: C. Bollard, Washington, DC vs B. Burkhardt, Muenster

Aula Magna (Lugano University)
RADIOTHERAPY FOR LYMPHOMAS
Chair: L. Specht, Copenhagen (Denmark)
Discussants: R.T. Hoppe, Stanford vs G. Mikhaeel, London (UK)

09:00 – 10:30 Room B and Marquee
Abstract number
SESSION 1 – LYMPHOMA BIOLOGY
Co-chairs: R. Küppers, Essen (Germany) and M.A. Shipp, Boston, MA (USA)

09:00 041 GB VIRUS-C (GBV-C) INFECTION AND RISK OF LYMPHOMA: A CASE-CONTROL STUDY FROM NORTH AMERICA
A. Fama, Rochester, MN (USA)

09:15 042 DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE DISORDERS
S. Dietrich, Heidelberg (Germany)

09:30 043 ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL-LIKE (ABC) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
V. Priebe, Bellinzona (Switzerland)

09:45 044 NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS
F. Pozzo, Aviano (Italy)

10:00 045 ACTIVATION OF RHOA-VAV1 SIGNALING IN ANGIOMUNOBLASTIC T-CELL LYMPHOMA
M. Sakata-Yanagimoto, Ibaraki (Japan)

10:15 046 TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA
R.L. Boddicker, Rochester, MN (USA)

10:30 – 11:00 COFFEE BREAK

11:00 – 12:00 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)
SESSION 2 – PRIMARY MEDIASTINAL B-CELL LYMPHOMA
Co-chairs: A.J. Davies, Southampton (UK) and G.S. Nowakowski, Rochester, MN (USA)

11:00 047 MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT
A. Mottok, Vancouver (Canada)
11:15 048 METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA
L. Ceriani, Bellinzona (Switzerland)

11:30 049 OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA TREATED WITH DOSE-ADJUSTED EPOCH-R THERAPY: A MULTICENTER RETROSPECTIVE ANALYSIS
L.G. Roth, New York, NY (USA)

11:45 050 EFFICACY AND SAFETY OF PEMBROLIZUMAB IN RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (rrPMBCL): INTERIM ANALYSIS OF THE KEYNOTE-170 PHASE 2 TRIAL
P.L. Zinzani, Bologna (Italy)

12:00 – 13:00 LUNCH TIME AND POSTER VIEWING
from 12:30 to 13:00 authors in front of their poster for discussion with attendees

13:00 – 13:45 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)
002 GENETIC SIGNATURES AND TARGETABLE PATHWAYS IN LYMPHOID MALIGNANCIES
M.A. Shipp, Boston, MA (USA)

13:15 – 16:45 Auditorium (Lugano University)
WORKSHOP - CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES
Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and J. Yahalom, New York, NY (USA)
Organized by International Lymphoma Radiation Oncology Group – ILROG
open to all 14-ICML attendees

13:15 A.K. Ng, Boston, MA (USA)
13:30 C. Thieblemont, Paris (France)
13:45 U. Ricardi, Turin (Italy)
14:00 Case oriented discussion: A.K. Ng, Boston (USA), C. Thieblemont, Paris (France), U. Ricardi, Turin (Italy), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)

14:15 – 14:25 BREAK

14:25 J. Yahalom, New York, NY (USA)
14:40 G. Salles, Lyon (France)
14:55 G. Mikhaeel, London (UK)
15:10 Case oriented discussion: J. Yahalom, New York, NY (USA), G. Salles, Lyon (France), G. Mikhaeel, London (UK) and M.K. Gospodarowicz, Toronto (Canada)

15:25 – 15:45 COFFEE BREAK - inside Auditorium (Lugano University) for workshop attendees
APPROACHES TO REDUCE LATE EFFECTS OF LYMPHOMA TREATMENT
B.S. Dabaja, Houston, TX (USA):
IS PROTON THERAPY THE ANSWER?
16:00 D. Hodgson, Toronto (Canada): STRATEGIES TO REDUCE THE RISK OF SECOND MALIGNANCIES
16:15 L. Specht, Copenhagen (Denmark): STRATEGIES TO REDUCE THE RISK OF CARDIOVASCULAR LATE EFFECTS
16:30 Discussion: B.S. Dabaja, Houston, TX (USA), D. Hodgson, Toronto (Canada), L. Specht, Copenhagen (Denmark), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)

SESSION 3 – HODGKIN LYMPHOMA
Co-chairs: V. Diehl, Cologne (Germany) and A. Pavlovsky, Buenos Aires (Argentina)

13:45 – 15:15
Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

13:45 051 RESTORE & TARGET: A CONCEPTUALLY NOVEL TREATMENT APPROACH TO CLASSICAL HODGKIN’S LYMPHOMA
C. Schmitt, Berlin (Germany)

14:00 052 GENOTYPING OF CLASSICAL HODGKIN LYMPHOMA ON THE LIQUID BIOPSY
A. Bruscaggin, Bellinzona (Switzerland)

14:15 053 eBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM-PET-POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL
P. Borchmann, Cologne (Germany)

14:30 054 RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER A NEGATIVE INTERIM PET SCAN (CRUK/07/033)
J. Trotman, Concord (Australia)

14:45 055 BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI–PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (cHL)
R. Chen, Duarte, CA (USA)

15:00 056 COMBINED RISK OF SECOND MALIGNANT NEOPLASMS AND CARDIOVASCULAR DISEASE IN LONG-TERM HODGKIN LYMPHOMA SURVIVORS
B.M. Aleman, Amsterdam (The Netherlands)

15:15 – 15:30
Marquee, Cinema Corso and Aula Magna (Lugano University)

15:30 – 17:00
2 parallel sessions

SESSION 4 – TARGETING THE BCR PATHWAYS
Co-chairs: J.F. Seymour, Melbourne (Australia) and C. Thieblemont, Paris (France)

15:30 057 CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM A PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
G. Lenz, Muenster (Germany)
15:45 058  DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
P.L. Zinzani, Bologna (Italy)

16:00 059  BRUTON’S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
J. Trotman, Concord (Australia)

16:15 060  IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE LOC PHASE II STUDY FROM THE LYS A AND THE FRENCH LOC NETWORK
C. Soussain, Saint-Cloud (France)

16:30 061  TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF A PHASE 1 STUDY
J. Kaplan, Chicago, IL (USA)

16:45 062  THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES
P.A. Hamlin, Basking Ridge, NJ (USA)

15:30 – 17:00 Room B and Marquee

SESSION 5 – T-CELL LYMPHOMAS
Co-chairs: K. Tobinai, Tokyo (Japan) and J.M. Vose, Omaha, NE (USA)

15:30 063  GENE EXPRESSION PROFILING USING A RTMLPA ASSAY ALLOWS FOR AN ACCURATE CLASSIFICATION OF PERIPHERAL T-CELL LYMPHOMA AND HIGHLIGHTS NOVEL SUBGROUPS WITHIN PTCLs-NOS
P. Ruminy, Rouen (France)

15:45 064  CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA: INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO-T TRIAL
M. Gleeson, Sutton (UK)

16:00 065  ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS: A PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYS A CENTERS
G. Fossard, Pierre Bénite (France)

16:15 066  BRENTUXIMAB VEDOTIN VS PHYSICIAN’S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION
Y.H. Kim, Stanford, CA (USA)

16:30 067  IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT
C.P. Fox, Nottingham (UK)

16:45 068  GAD-M REGIMEN FOR NEWLY DIAGNOSED EXTRANODAL NK/T CELL LYMPHOMA: ANALYSIS OF EFFICACY AND SAFETY FROM PHASE II STUDY (NCT 019991158)
Z. Li, Guang Zhou (China)

17:00 -17:15 BREAK
Thursday, June 15, 2017 (continued)

17:15 – 18:15 “FOCUS ON…” SESSIONS
5 parallel sessions

Room A

TARGETING CD30 IN HODGKIN LYMPHOMA
Chair: A. Engert, Cologne (Germany)

17:15 069 RESULTS OF A PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY)
A. Gibb, Manchester (UK)

17:25 070 BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN PATIENTS WITH LIMITED STAGE NON-BULKY HODGKIN LYMPHOMA: AN UPDATE FROM A PHASE 2 CLINICAL TRIAL
S.I. Park, Charlotte, NC (USA)

17:35 071 RESULTS OF A MULTICENTRE UK-WIDE STUDY EVALUATING THE EFFICACY OF BRENTUXIMAB VEDOTIN IN RELAPSED, REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN THE PRE-TRANSPLANT NAÏVE SETTING
T.A. Eyre, Oxford (UK)

17:45 072 BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY
A. Bazarbachi, Beirut (Lebanon)

17:55 073 SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)
C.S. Diefenbach, New York, NY (USA)

Room B and Marquee

NOVEL ANTI-LYMPHOMA STRATEGIES
Chair: P.W.M. Johnson, Southampton (UK)

17:15 075 CLARITHROMYCIN AS A “REPURPOSING DRUG” AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL)
A.J. Ferreri, Milan (Italy)

17:25 076 A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL)
J.E. Amengual, New York, NY (USA)

17:35 077 CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR-DLBCL) - OUTCOME OF IBRUTINIB + R-GDP
J. Kuruvilla, Kingston (Canada)

17:45 078 EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL
A. Pettitt, Liverpool (UK)
17:55 079 VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL); FINAL RESULTS OF A PHASE I STUDY
L.J. Swinnen, Baltimore, MD (USA)

18:05 080 POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
H. Tilly, Rouen (France)

Cinema Corso

CLINICO-GENETIC RISK MODELS
Chair: P. Gaulard, Créteil (France)

17:15 081 APPLICATION OF A GENE EXPRESSION-BASED MODEL IN COMBINATION WITH FDG-PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033)
C.H. Burton, Leeds (UK)

17:25 082 THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL
D.W. Scott, Vancouver (Canada)

17:35 083 GENE MUTATIONS AND COPY NUMBER ALTERATIONS (CNA) PREDICT FOR EARLY FAILURE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP
I. Dlouhy, Barcelona (Spain)

17:45 084 KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL
S. Ferrero, Turin (Italy)

17:55 085 BASELINE CIRCULATING CELL-FREE DNA LOAD IS RELATED TO, BUT ADDS PROGNOSTIC VALUE TO METABOLIC TUMOR BURDEN MEASURED BY FDG PET/CT IN FOLLICULAR LYMPHOMA
M.H. Delfau-Larue, Creteil (France)

18:05 086 EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL
S. Huet, Pierre Bénite (France)
Travel Grant Winner (sponsored by Swiss Cancer Research Foundation)

Auditorium (Lugano University)

ONGOING TRIALS
Chair: M. Dreyling, Munich (Germany)

17:15 OT01 ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP VS PLACEBO/R-CHOP IN UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING
A. Chiappella, Turin (Italy)

17:25 OT02 PHASE II STUDY OF DURVALUMAB (ANTI–PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
U. Jäger, Vienna (Austria)
17:35 OT03 CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA
L. Nayak, Boston, MA (USA)

17:45 OT04 MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND A RITUXIMAB-LENALIDOMIDE MAINTENANCE
V. Ribrag, Villejuif (France)

17:55 OT05 PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL)
C.S. Tam, Melbourne (Australia)

18:05 OT06 A HEAD-TO-HEAD PHASE 3 STUDY COMPARING BGB-3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
C. Buske, Ulm (Germany)

Aula Magna
Lugano University
LYMPHOMA IN THE ELDERLY
Chair: U. Vitolo, Turin (Italy)

17:15 087 HIGHER AGE IS ASSOCIATED WITH INCREASED MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA
S. Alig, Munich (Germany)

17:25 088 LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: A LYS A STUDY
M.H. Delfau-Larue, Creteil (France)

17:35 089 CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP
O. Al-Sawaf, Cologne (Germany)

17:45 090 UNMET MEDICAL NEEDS IN HODGKIN LYMPHOMA WITH SPECIAL FOCUS ON THE ELDERLY – A POPULATION-BASED STUDY OF PATIENTS DIAGNOSED IN SWEDEN 1973-2014
M. Björkholm, Stockholm (Sweden)

17:55 091 TREATMENT STRATEGIES AND OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA OF THE ELDERLY: A DANISH POPULATION-BASED COHORT STUDY OF 1,011 PATIENTS
M.B. Juul, Odense (Denmark)

18:05 092 REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH-RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R-CHOP
C. Thieblemont, Paris (France)

19:00 – 21:00  2 parallel symposia
Room A CELGENE MANAGEMENT OF B-CELL NON-HODGKIN LYMPHOMA: WHERE ARE WE NOW AND WHERE ARE WE GOING?
Chair: G. Salles, Lyon (France)

Room B MUNDIPHARMA MEDICAL COMPANY - TEVA ONCOLOGY CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
Chair: M. Ghielmini, Bellinzona (Switzerland)
Friday, June 16, 2017

08:00 – 08:45  **Article MEET THE PROFESSOR SESSIONS**

- **Room A**
  - IV  ROLE AND TIMING OF NEW DRUGS IN CLL
    - M. Hallek, Cologne (Germany)

- **Room B and Marquee**
  - VII  THE MULTIPLE FACETS OF MARGINAL ZONE LYMPHOMAS
    - M. Raderer, Vienna (Austria)

- **Cinema Corso**
  - VI  THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS
    - L. Quintanilla-Martinez, Tuebingen (Germany)

- **Auditorium (Lugano University)**
  - X  LATE SEQUELAE IN HODGKIN LYMPHOMA SURVIVORS
    - F.E. Van Leeuwen, Amsterdam (The Netherlands)
    - offered only once

- **Aula Magna (Lugano University)**
  - VIII  MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS
    - C. Thieblemont, Paris (France)

08:30 – 18:30  **POSTER SESSION**

09:00 – 10:30  **“CASE DISCUSSION” SESSIONS**

- **Room A**
  - AGGRESSIVE LYMPHOMAS
    - Chair: S. Le Gouill, Nantes (France)
    - Discussants: S. De Vos, Santa Monica vs G. Lenz, Muenster

- **Cinema Corso**
  - INDOLENT LYMPHOMAS
    - Chair: A. Lopez-Guillermo, Barcelona (Spain)
    - Discussants: T.J. Kipps, La Jolla vs M. Dreyling, Munich

- **Auditorium (Lugano University)**
  - CLL
    - Chair: J.G. Gribben, London (UK)
    - Discussants: S.M. O’Brien, Orange vs S. Stilgenbauer, Ulm

- **Aula Magna (Lugano University)**
  - DIFFICULT PATHOLOGICAL CASES
    - Chair: M. Ghielmini, Bellinzona (Switzerland)
    - Presenters: E. Campo, Barcelona (Spain), S. Dirnhofer, Basel (Switzerland), L. Quintanilla-Martinez, Tuebingen (Germany)
    - Discussants: S.T. Rosen, Duarte vs U. Dührsen, Essen

09:00 – 10:30  **SESSION 6 – LYMPHOMA GENOMICS**

- **Room B and Marquee**
  - A SINGLE-CELL BASED MODEL EXPLAINS PATTERNS OF CLONAL EVOLUTION IN PRIMARY AND RELAPSED FOLLICULAR LYMPHOMA
    - M. Löffler, Leipzig (Germany)

09:00  093  FULL TRANSCRIPTOME SEQUENCING OF SORTED HODGKIN AND REED-STERNBERG CELLS REVEALS PLASMACYTIC DIFFERENTIATION: INSIGHTS INTO MECHANISMS OF ONCOGENESIS AND IMMUNE EVASION

- M. Roshal, New York, NY (USA)
09:30 095 PROFILING OF DNA METHYLATION IN EPIDEMIOLOGICAL AND CLINICAL SUBGROUPS OF BURKITT LYMPHOMA IN THE FRAMEWORK OF THE MMML: ICGC AND BLUEPRINT CONSORTIA
R. Wagener, Ulm (Germany)

09:45 096 MUTATIONAL SIGNATURES IN GERMINAL CENTER DERIVED B-CELL LYMPHOMAS FROM ADULT PATIENTS ANALYZED IN THE ICGC MMML-SEQ CONSORTIUM
D. Huebschmann, Heidelberg (Germany)

10:00 097 CROSS-PLATFORM VALIDATION OF GENE EXPRESSION PROFILING (GEP) BASED CELL OF ORIGIN (COO) CLASSIFICATION IN A CLINICAL LABORATORY SETTING
S. Barrans, Leeds (UK)

10:15 098 THE LANDSCAPE OF SOMATIC MUTATIONS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG-TYPE
F. Jardin, Rouen (France)

10:30 – 10:50 COFFEE BREAK

10:50 – 12:05 Marquee
10:50 – 12:05 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

SESSION 7 – ADVANCES IN CLL
Co-chairs: N. Chiorazzi, Manhasset, NY (USA) and B. Eichhorst, Cologne (Germany)

10:50 099 INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49d: CLINICAL RELEVANCE
E. Tissino, Aviano (Italy)

11:05 100 INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS
T.J. Kipps, La Jolla, CA (USA)

11:20 101 UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY
A. Mato, Philadelphia, PA (USA)

11:35 102 CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL
L.J. Nastoupil, Houston, TX (USA)

11:50 103 SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
C.S. Tam, Melbourne (Australia)

12:05 – 13:00 Marquee

LUNCH TIME AND POSTER VIEWING
from 12:30 to 13:00 authors in front of their poster for discussion with attendees
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 13:45</td>
<td><strong>JOHN ULTMANN MEMORIAL LECTURE</strong>&lt;sup&gt; الفرنسي&lt;/sup&gt;</td>
<td>Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)</td>
<td>Chair: E. Campo, Barcelona (Spain) sponsored by European School of Oncology – ESO</td>
</tr>
<tr>
<td></td>
<td>GENOMES IN TRANSIT: WHAT MULTI-OMICS CAN TELL US ON LYMPHOMAS</td>
<td></td>
<td>R. Siebert, Ulm (Germany)</td>
</tr>
<tr>
<td>13:45 – 15:15</td>
<td><strong>SESSION 8 – FOLLICULAR LYMPHOMA</strong></td>
<td>Room A, B, Marquee and Cinema Corso</td>
<td>Co-chairs: B.S. Kahl, St. Louis, MO (USA) and E. Kimby, Stockholm (Sweden)</td>
</tr>
<tr>
<td>13:45</td>
<td>104 GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA</td>
<td></td>
<td>S. Huet, Pierre Bénite (France)</td>
</tr>
<tr>
<td>14:00</td>
<td>105 THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE</td>
<td></td>
<td>M. Federico, Modena (Italy)</td>
</tr>
<tr>
<td>14:15</td>
<td>106 PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC Tumor VOLUME AND END INDUCTION PET: A POOLED ANALYSIS FROM LYSY AND FIL TRIALS</td>
<td></td>
<td>A. Cottereau, Paris (France)</td>
</tr>
<tr>
<td>14:30</td>
<td>107 IMMUNOCHEMOTHERAPY WITH OBIQUITUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN</td>
<td></td>
<td>W. Hiddemann, Munich (Germany)</td>
</tr>
<tr>
<td>14:45</td>
<td>108 COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1)</td>
<td></td>
<td>M. Dreyling, Munich (Germany)</td>
</tr>
<tr>
<td>15:00</td>
<td>109 HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN-LABEL, PHASE II STUDY</td>
<td></td>
<td>L.J. Nastoupil, Houston, TX (USA)</td>
</tr>
<tr>
<td>14:15 – 17:15</td>
<td><strong>IBSA FOUNDATION SPECIAL FORUM - BASIC MECHANISMS OF CANCER IMMUNOTHERAPY</strong></td>
<td>Auditorium (Lugano University)</td>
<td>Chair: A. Alimonti, Bellinzona (Switzerland) Organized by IBSA Foundation for Scientific Research open to all 14-ICML attendees, appreciated pre-registration at <a href="http://www.ibsafoundation.org">www.ibsafoundation.org</a> (free session)</td>
</tr>
<tr>
<td>14:15</td>
<td>WELCOME</td>
<td></td>
<td>S. Misiti Lugano (Switzerland)</td>
</tr>
<tr>
<td>14:20</td>
<td>INTRODUCTION</td>
<td></td>
<td>A. Alimonti, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>14:30</td>
<td>IMMUNOTHERAPY HAS COME OF AGE</td>
<td></td>
<td>R. Levy, Stanford, CA (USA)</td>
</tr>
</tbody>
</table>
IMMUNOGENIC CELL DEATH: EXPLAINING THE SUCCESS OF CANCER THERAPIES
G. Kroemer, Paris (France)

COFFEE BREAK - inside Auditorium (Lugano University) for attendees

WHY THE IMMUNE RESPONSE IN LYMPHOMA IS INADEQUATE
F. Caligaris-Cappio, Milan (Italy)

PRE-CLINICAL DEVELOPMENT OF NOVEL COMBINATORIAL THERAPIES AGAINST MYC/BCL2 DOUBLE-HIT LYMPHOMA
B. Amati, Milan (Italy)

UCLI-ICML JOINT SESSION - NATURAL KILLER / T-CELL (NK/T-CELL) LYMPHOMA
Co-chairs: J.M. Vose, Omaha, NE (USA), J. Zhu, Beijing (China) and Y.-K. Shi, Beijing (China)
Organized in collaboration with Union of Chinese Lymphoma Investigators - UCLI

NON-CANONICAL ROLE OF EZH2 IN NK / T-CELL LYMPHOMA
W.-J. Chng, Singapore (Singapore)

EBV-ASSOCIATED NODAL T AND NK-CELL LYMPHOMA SHOWS DISTINCT MOLECULAR SIGNATURE AND COPY NUMBER CHANGES
W.-J. Chng, Singapore (Singapore)

NK/T-CELL LYMPHOMA: WHEN PATIENTS MEET OMICS
W.-L. Zhao, Shanghai (China)

TREATMENT OF EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE (ENKTL)
W.S. Kim, Seoul (South Korea)

COFFEE BREAK - inside Aula Magna (Lugano University) for attendees

FIRST-LINE L-ASPARAGINASE-BASED CHEMOTHERAPY PLUS RADIOTHERAPY IS ACTIVE IN STAGE I/II EXTRANODAL NK/T-CELL LYMPHOMA: RESULTS FROM PEKING UNIVERSITY CANCER HOSPITAL
Y.-Q. Song, Beijing (China)

CURRENT TREATMENT FOR NK/T CELL LYMPHOMA: SUN YAT-SEN UNIVERSITY CANCER CENTER EXPERIENCE, CHINA
H.-Q. Huang, Guangzhou (China)

MOLECULAR CHARACTERIZATION OF EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMAS, NASAL TYPE FROM LATIN AMERICA
L. Quintanilla-Martinez, Tuebingen (Germany)

NK/T-CELL LYMPHOMA, THE FRENCH EXPERIENCE
A. Jaccard, Limoges (France)

COMMENTS
M. Federico, Modena (Italy), W.-Q. Jiang, Guangzhou (China) and X.-P. Lu, Shenzhen (China)

COFFEE BREAK
DESIGN OF FUTURE CLINICAL TRIALS: REPORT OF THE 14-ICML WORKSHOP
Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland)
A. Younes, New York, NY (USA)

SESSION 9 – AGGRESSIVE LYMPHOMAS
Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland)

15:50 – 17:20
Room A, B, Marquee and Cinema Corso

LONG-TERM SURVIVAL AND LOSS IN EXPECTANCY OF LIFE IN A POPULATION-BASED COHORT OF 7114 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
K.E. Smedby, Solna (Sweden)

16:05 119  R-CHOP +/- RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSÃ/GOELAMS
T. Lamy, Rennes (France)

16:20 120  RADIOTHERAPY TO BULKY DISEASE PET-NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF A PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL>60 STUDY OF THE DSHNHL
M. Pfreundschuh, Homburg (Germany)

16:35 121  DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBL): A PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMoDL-B
A.J. Davies, Southampton (UK)

16:50 122  PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY
U. Vitolo, Turin (Italy)

17:05 123  RISK-ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF A MULTICENTER PROSPECTIVE PHASE II STUDY OF DA-EPOCH-R
K. Dunleavy, Bethesda, MD (USA)

17:30 – 18:45  FAREWELL APERO
Marquee

ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND – IOSI
“THE BIG DEBATE: POINT COUNTER POINT” HAVE NEW DRUGS MADE STEM CELL TRANSPLANTATION OBSOLETE?
Chair: M. Ghielmini, Bellinzona (Switzerland)
Supported by Gilead Sciences Europe Ltd. who provided funding.

KITE PHARMA
ENGINEERED T-CELL THERAPY: CAR-T’S ESTABLISHING A NEW PARADIGM OF TREATMENT IN RELAPSED AND REFRACTORY NHL?
Chair: G. Salles, Lyon (France)
Co-chair: P. Dreger, Heidelberg (Germany)
Saturday, June 17, 2017

08:00 – 10:30
Room 156
(Lugano University)

SPECIAL SESSION - CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING
A.K. Berthelsen, Copenhagen (Denmark) and L. Specht, Copenhagen (Denmark)
Organized by International Lymphoma Radiation Oncology Group - ILROG and European Society for Radiotherapy and Oncology – ESTRO

Compulsory pre-registration up to 30 attendees at registration@lymphcon.ch (fee CHF 50.-)

08:30 – 10:00
2 parallel sessions

Room A

SESSION 10 – IMMUNOTHERAPIES
Co-chairs: R. Levy, Stanford, CA (USA) and D.G. Maloney, Seattle, WA (USA)

08:30 124  CD27 STIMULATION ENHANCES CD20 MAB THERAPY THROUGH ACTIVATION OF INNATE IMMUNITY
S.H. Lim, Southampton (UK)

08:45 125  NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL
M. Fanale, Houston, TX (USA)

09:00 126  PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY
P.L. Zinzani, Bologna (Italy)

09:15 127  A PHASE Ib STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
M.L. Palomba, New York, NY (USA)

09:30 128  HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B-NHL TREATED WITH THE CD19-DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001)
J. Abramson, Boston, MA (USA)

09:45 129  A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
C. Sauter, New York, NY (USA)

Room B

SESSION 11 – MANTLE CELL LYMPHOMA
Co-chairs: U. Novak, Bern (Switzerland) and G. Salles, Lyon (France)

08:30 130  P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE INDEPENDENT OF MIPI AND KI-67 IN PROSPECTIVE TRIALS OF THE EUROPEAN-MCL NETWORK
M. Dreyling, Munich (Germany)

08:45 131  FIRST-LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R-CHOP/R-CVP: RESULTS OF THE BRIGHT 5-YEAR FOLLOW-UP STUDY
T. Hawkins, Auckland (New Zealand)

09:00 132  FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF A LYSA GROUP TRIAL
R. Gressin, Grenoble (France)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15</td>
<td>IBRUTINIB-RITUXIMAB FOLLOWED BY REDUCED CHEMO-IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: A WINDOW OF OPPORTUNITY TO REDUCE CHEMO</td>
<td>M.L. Wang, Houston, TX (USA)</td>
</tr>
<tr>
<td>09:30</td>
<td>IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY</td>
<td>S. Rule, Plymouth (UK)</td>
</tr>
<tr>
<td>09:45</td>
<td>COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY</td>
<td>C.S. Tam, Melbourne (Australia)</td>
</tr>
<tr>
<td>10:00</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>SESSION 12 – MARGINAL ZONE LYMPHOMA</td>
<td>Co-chairs: A. Lopez-Guillermo, Barcelona (Spain) and S. Montoto, London (UK)</td>
</tr>
<tr>
<td>10:15</td>
<td>INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION</td>
<td>M. Frigeni, Pavia (Italy)</td>
</tr>
<tr>
<td></td>
<td>Travel Grant Winner (sponsored by Swiss Cancer Research Foundation)</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN A SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)</td>
<td>M. Herold, Erfurt (Germany)</td>
</tr>
<tr>
<td>10:45</td>
<td>LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01)</td>
<td>A. Salar, Barcelona (Spain)</td>
</tr>
<tr>
<td>11:00</td>
<td>PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA</td>
<td>M. Coleman, New York, NY (USA)</td>
</tr>
<tr>
<td>11:15</td>
<td>14-ICML HIGHLIGHTS</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>“TAKE HOME MESSAGES”</td>
<td>J.W. Friedberg, Rochester, NY (USA)</td>
</tr>
<tr>
<td>11:40</td>
<td>CLOSURE AND FAREWELL</td>
<td>F. Cavalli, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>13:30</td>
<td>WORKSHOP - NEW DEVELOPMENTS IN CANINE LYMPHOMA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-chairs: S. Comazzi, Milan (Italy), F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy) Organized by the European Canine Lymphoma Network open to all 14-ICML attendees</td>
<td></td>
</tr>
</tbody>
</table>
14-ICML TRANSPORT SERVICE

Ticino Public Transport

14-ICML Transport Info Desk is available in the Main Hall, with the same working hours as the Registration desk.

- 14-ICML attendees who booked their accommodation in Ticino (the region where Lugano is the main town) will receive UPON HOTEL CHECK IN “Ticino Ticket”, a public transport ticket, valid for the length of their stay, valid on all the public transports in Ticino.
- An OneWay Ticket to reach booked hotels is available at the 14-ICML Transport Info Desk.

For further information on “Ticino Ticket” please visit http://www.ticino.ch/en/ticket.html

- 14-ICML attendees who did not book their accommodation in Ticino will receive a public transport ticket, valid from Tuesday 13 to Saturday 17, for all the public transports in Ticino AT THE 14-ICML TRANSPORT INFO DESK.

14-ICML Transport Service

For those hotels which are not in Ticino or are not very well served by public transports (and only for those who confirmed the hotel reservation through Amiconi Consulting), ICML Secretariat organize extra transports from hotel to convention center and vice versa.

The buses schedule and timetable is available at the ICML official website (www.lymphcon.ch), on the 14-ICML APP and at the Transport Info Desk. The arrival / departure point is CAMPO MARZIO PARKING.

Private Transports

Viale Cattaneo, the street connecting Lugano city center to Castagnola and running along Palazzo dei Congressi and Parco Ciani, is a two-way street.

During ICML, it will be one way only (direction: from city center to Castagnola) from Tuesday 13 to Friday 16 from 17:30 to 22:00 to permit private transport passenger boarding and alighting.

Outside this allowed time slot, Campo Marzio Parking is the passenger boarding and alighting appointed space.

14-ICML Shuttle Service

A shuttle service connects the conference locations with the following timetable:

- on Tuesday 13 from 18:30 to 21:30 (connecting Palazzo dei Congressi and Campo Marzio Parking only)
- from Wednesday 14 to Friday 16 from 07:30 to 11:00 and from 17:00 to 22:00 (connecting Palazzo dei Congressi, Campo Marzio Parking and Lugano University)
- on Saturday 17 from 07:30 to 10:30 (connecting Palazzo dei Congressi and Campo Marzio Parking only)

Please note that, on this service, attendees with physical disabilities have precedence.

Further Information:

- Thursday 15 is bank holiday in Ticino and public transportation might run less frequently than on ordinary working days
- A cable railway connects Lugano Train Station to the center of the city, running daily from 07:00 to 19:00 (on Thursday 15 and Saturday 17 from 08:00 to 16:00 only)
- Lugano City Taxis are available outside the main entrance of Palazzo dei Congressi
- Lugano long lake will be closed to traffic on Friday 16 from 19:30.
14-ICML CONTACTS

Conference Secretariat

14-ICML Secretariat
IOSI - Oncology Institute of Southern Switzerland
Ospedale San Giovanni
CH-6500 Bellinzona
Tel. +41 91 922 05 75
Fax +41 91 922 20 84
Website: www.lymphcon.ch

Foundation for the Research and Cure of Lymphoma in Ticino (Fondazione per la Ricerca e la Cura dei Linfomi nel Ticino)
vat number: CHE-110.407.651 IVA
IOSI - Oncology Institute of Southern Switzerland
Ospedale San Giovanni
CH-6500 Bellinzona
www.lymphcon.ch

ICML President:
Prof. Dr. Franco Cavalli
Tel: +41 91 811 86 66
Fax: +41 91 811 80 56
franco.cavalli@eoc.ch

Chairman Local Organizing Committee:
Prof. Dr. Michele Ghielmini
Tel: +41 91 811 94 10
Fax: +41 91 811 87 31
michele.ghielmini@eoc.ch

Cristiana Brentan
general coordination and information, scientific program, abstracts
e-mail: cristiana.brentan@lymphcon.ch

Orietta Lugli
exhibition management, satellite symposia, sponsorships, ancillary meetings
e-mail: orietta.lugli@lymphcon.ch

Chiara Saporiti
Group and individual registrations, accounting
e-mail: registration@lymphcon.ch

14-ICML Official Partners

Eventmore
In charge of any technical aspect of conference sessions, satellite symposia and ancillary meetings held in Palazzo dei Congressi, Marquee Parco Ciani, University of Lugano, Cinema Corso and Villa Ciani
Via S. Gottardo 18D
CH-6532 Castione
Tel: +41 (0)91 850 10 60
Fax: +41 (0)91 850 10 61
info@eventmore.ch
www.eventmore.ch

Amiconi Consulting SA
In charge of hotel accommodation and “tours and guest’s” program. Amiconi Consulting can also provide the following services: meeting facilities (outside the Conference Venue), dinner reservations for groups, transfers services from/to the hotels/restaurants and the conference centre.
Via al Forte 10
CH - 6900 Lugano
Tel. +41 (0)91 921 38 12
Fax +41 (0)91 921 38 13
info@amiconiconsulting.ch
www.amiconiconsulting.ch
Keep looking

Shouldn’t we strive to improve frontline treatment outcomes in patients with advanced-stage Hodgkin lymphoma?

- Current treatments have a failure rate of approximately 30%1,4
- Toxicities are unpredictable and, in some cases, fatal2,7
- Treatment can reduce patients’ quality of life in the short and long term8,9

Until we solve these issues, we need to keep looking

*28–36% of advanced-stage patients treated with ABVD will require additional therapy, progress, or die within 3 years1,4

Visit Booth 12 to find out more


Takeda Oncology is a trademark of Takeda Pharmaceutical Company Limited. Millennium Pharmaceuticals, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

©2017 Millennium Pharmaceuticals, Inc.